Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (EYPT) announced its Q3 2022 financial results, reporting net product revenue of $9.7 million, a 13% increase from Q3 2021. The company initiated two Phase 2 clinical trials for EYP-1901 targeting wet AMD and NPDR. Management stated that these trials stem from positive Phase 1 results, presented at major ophthalmology meetings. Operating expenses rose to $28.4 million, while net loss reached $18.4 million or ($0.49) per share. The company anticipates funding through mid-2024, supported by its cash reserves of $157.3 million.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call and live webcast on November 2, 2022, at 8:30 a.m. ET to report its Q3 2022 financial results and discuss corporate developments. The company focuses on developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained intraocular drug delivery. Currently, EYPT is advancing EYP-1901, a Phase 2 clinical trial treatment. The call will be accessible via a registration link and a replay will be available on the company's website after the event.
On October 14, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted non-statutory stock options to 12 new employees, totaling 42,900 shares. The options have an exercise price of $5.60 per share, coinciding with the closing stock price on that date. These options are part of a strategy to attract talent and are subject to a four-year vesting schedule. EyePoint's proprietary Durasert technology is being utilized in their pipeline, notably EYP-1901, which is in Phase 2 trials for sustained delivery of anti-VEGF treatment. The company focuses on therapeutics for serious eye disorders.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated the first patient dosing in the Phase 2 PAVIA clinical trial for EYP-1901, targeting non-proliferative diabetic retinopathy (NPDR). This trial aims to evaluate the treatment's efficacy and safety in approximately 105 patients. EYP-1901 utilizes a sustained delivery method to potentially improve vision and reduce complications. Phase 1 results showed promising safety and efficacy, with significant percentages of patients not needing further anti-VEGF injections. The trial's primary endpoint is a two-level improvement in diabetic retinopathy severity by week 36.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the granting of non-statutory stock options to four new employees as inducement awards, compliant with NASDAQ Listing Rule 5635(c)(4). The grants, totaling 19,700 shares, were approved on September 15, 2022, with an exercise price of $7.99 per share, reflecting the stock's closing price that day. These options vest over four years, contingent on the employees' continued service. EyePoint focuses on developing therapeutics for serious eye disorders, utilizing its Durasert® technology.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) has announced its participation in several upcoming conferences aimed at improving the lives of patients with serious eye disorders. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 a.m. ET, and at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 1:25 p.m. ET. Additionally, a Fireside Chat at the Guggenheim Nantucket Therapeutics Conference is scheduled for September 29, 2022, at 10:30 a.m. ET, followed by another on September 30, 2022, at 11:40 a.m. ET during the Benzinga Retail Conference.
EyePoint Pharmaceuticals reported a significant milestone with the first patient dosed in the Phase 2 DAVIO 2 clinical trial for wet AMD. The Phase 1 DAVIO results showcased a promising safety and efficacy profile for EYP-1901. Financially, the company achieved a 30% increase in net product revenue, totaling $11.3 million in Q2 2022. Operating expenses increased to $30.8 million, leading to a net loss of $19.4 million. The company is positioned to fund operations into 2024, buoyed by robust demand for products like YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) recently announced its participation in two upcoming conferences. The BTIG Biotechnology Conference is scheduled for August 9, 2022, at 10:00 a.m. ET, featuring a panel discussion. Additionally, the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference will take place on August 17, 2022, with corporate presentations at 7:00 a.m. ET and 11:00 a.m. ET. Webcasts of both events will be available on the company's website, with replays accessible for 90 days.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the dosing of the first patient in the Phase 2 DAVIO 2 clinical trial for EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial utilizes a 'Treat to Maintain' strategy, potentially reducing treatment frequency, as shown by Phase 1 results where 53% of patients didn't require additional treatment for six months. The Phase 2 trial will enroll around 150 patients, investigating the efficacy of EYP-1901 compared to aflibercept. Topline data is anticipated in the second half of 2023.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 3, 2022, at 8:30 a.m. ET to discuss its Q2 2022 financial results and recent corporate developments. The company focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its pipeline includes EYP-1901, targeting wet age-related macular degeneration. EyePoint's current marketed product is YUTIQ®, approved for chronic non-infectious uveitis. Interested parties can access the call via registration or by visiting the company website for a live audio webcast.